Key Leadership Appointments at Berlex

Apr 24, 2001, 01:00 ET from Berlex Laboratories, Inc.

    MONTVILLE, N.J., April 24 /PRNewswire Interactive News Release/ -- Dale
 Stringfellow, Ph.D, president and chief executive officer of Berlex
 Laboratories, Inc., a U.S. affiliate of Schering AG, Germany (NYSE:   SHR),
 today announced the appointment of Alice Leung as vice president and general
 manager of the Berlex oncology business unit, and Ralph Makar, as vice
 president, marketing, of the Berlex therapeutics business unit.
     "With the Berlex portfolio rapidly expanding over the next two years, our
 priorities are to fully leverage the current brands and ensure excellent
 execution of the many upcoming product launches.  Together with our
 outstanding team, accomplished leaders like Alice and Ralph will be
 instrumental in driving the full potential of the portfolio," Dr. Stringfellow
 said.
     As a member of the executive operating committee, Ms. Leung will design
 the strategies and lead implementation of the tactics needed to fortify the
 presence and prospects for Berlex's oncology portfolio, whose brands include
 Fludara(R)(fludarabine) and Quadramet(R) (Samarium Sm 153 Lexidronam
 Injection.)  The company anticipates launching Campath (alemtuzumab), which
 was recommended for approval by an FDA advisory committee in December 2000.
 She joins Berlex from Bristol-Myers Squibb Company where she was vice
 president, worldwide licensing and external development. During her 15-year
 association there, she managed the growth of some of the world's leading
 oncology treatments and participated in strategy oversight as a member of the
 research institute's management team.  A graduate of the University of Western
 Ontario in London, Canada, she earned an MBA from the Johnson School of
 Management, Cornell University.
     Ralph Makar joined the company to provide marketing vision and strategic
 focus for Berlex therapeutics leadership brands including
 Betaseron(R)(interferon beta-1b), the pioneering treatment for multiple
 sclerosis, and Betapace(R)/Betapace(R) AF (sotalol HCl), as well as new
 product entries, co-promotions and other new business opportunities.  Prior to
 joining Berlex, he was senior director on the U.S. cardiovascular disease team
 at Parke-Davis, Division of Warner Lambert with primary responsibility for
 marketing Lipitor(R)(atorvastatin), the multibillion-dollar leader in the
 atherosclerosis market. He previously implemented global launch strategies for
 a blockbuster antihypertensive at Novartis Pharmaceuticals, and managed many
 of that company's key brands. He began his career as a sales associate with
 Eli Lilly and Company.  A registered pharmacist and a graduate of the Rutgers
 College of Pharmacy, Mr. Makar earned an MBA from Columbia Business School.
     Berlex Laboratories, Inc. is a U.S. affiliate of Schering AG Germany, a
 research-based specialty pharmaceutical company and the world leader in
 fertility control and diagnostic imaging products. It markets well-established
 treatments for disabling diseases including multiple sclerosis and leukemia.
 Berlex has business operations in Montville and Wayne, New Jersey and in
 Richmond, California.  For more information about Berlex and its products,
 visit our website at http://www.berlex.com.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X48762762
 
 

SOURCE Berlex Laboratories, Inc.
    MONTVILLE, N.J., April 24 /PRNewswire Interactive News Release/ -- Dale
 Stringfellow, Ph.D, president and chief executive officer of Berlex
 Laboratories, Inc., a U.S. affiliate of Schering AG, Germany (NYSE:   SHR),
 today announced the appointment of Alice Leung as vice president and general
 manager of the Berlex oncology business unit, and Ralph Makar, as vice
 president, marketing, of the Berlex therapeutics business unit.
     "With the Berlex portfolio rapidly expanding over the next two years, our
 priorities are to fully leverage the current brands and ensure excellent
 execution of the many upcoming product launches.  Together with our
 outstanding team, accomplished leaders like Alice and Ralph will be
 instrumental in driving the full potential of the portfolio," Dr. Stringfellow
 said.
     As a member of the executive operating committee, Ms. Leung will design
 the strategies and lead implementation of the tactics needed to fortify the
 presence and prospects for Berlex's oncology portfolio, whose brands include
 Fludara(R)(fludarabine) and Quadramet(R) (Samarium Sm 153 Lexidronam
 Injection.)  The company anticipates launching Campath (alemtuzumab), which
 was recommended for approval by an FDA advisory committee in December 2000.
 She joins Berlex from Bristol-Myers Squibb Company where she was vice
 president, worldwide licensing and external development. During her 15-year
 association there, she managed the growth of some of the world's leading
 oncology treatments and participated in strategy oversight as a member of the
 research institute's management team.  A graduate of the University of Western
 Ontario in London, Canada, she earned an MBA from the Johnson School of
 Management, Cornell University.
     Ralph Makar joined the company to provide marketing vision and strategic
 focus for Berlex therapeutics leadership brands including
 Betaseron(R)(interferon beta-1b), the pioneering treatment for multiple
 sclerosis, and Betapace(R)/Betapace(R) AF (sotalol HCl), as well as new
 product entries, co-promotions and other new business opportunities.  Prior to
 joining Berlex, he was senior director on the U.S. cardiovascular disease team
 at Parke-Davis, Division of Warner Lambert with primary responsibility for
 marketing Lipitor(R)(atorvastatin), the multibillion-dollar leader in the
 atherosclerosis market. He previously implemented global launch strategies for
 a blockbuster antihypertensive at Novartis Pharmaceuticals, and managed many
 of that company's key brands. He began his career as a sales associate with
 Eli Lilly and Company.  A registered pharmacist and a graduate of the Rutgers
 College of Pharmacy, Mr. Makar earned an MBA from Columbia Business School.
     Berlex Laboratories, Inc. is a U.S. affiliate of Schering AG Germany, a
 research-based specialty pharmaceutical company and the world leader in
 fertility control and diagnostic imaging products. It markets well-established
 treatments for disabling diseases including multiple sclerosis and leukemia.
 Berlex has business operations in Montville and Wayne, New Jersey and in
 Richmond, California.  For more information about Berlex and its products,
 visit our website at http://www.berlex.com.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X48762762
 
 SOURCE  Berlex Laboratories, Inc.

RELATED LINKS

http://www.bms.com